文献速递眼底病与葡萄膜炎

利用真实世界数据评估视网膜脱离与局部毛果芸香碱使用的关联

Using Real-World Data to Assess the Association of Retinal Detachment With Topical Pilocarpine Use.
PubMed 文献 · Am J Ophthalmol · 2024-11-06

本研究为回顾性临床队列研究,利用TriNetX电子健康记录网络,比较40岁以上首次使用局部毛果芸香碱(1.25%或任何剂量且排除其他适应症)的成人患者与使用人工泪液的老视患者发生新发孔源性视网膜脱离(RRD)的风险。经倾向性评分匹配后,毛果芸香碱组3个月、6个月和1年RRD风险均显著高于对照组,Cox模型显示调整后风险增加3.14倍。

要点

  • 匹配后毛果芸香碱组3个月RRD风险0.53% vs 对照组0.25%(RR 2.18,95%CI 1.07-4.45,P=.03)。
  • 1年RRD风险毛果芸香碱组0.78% vs 对照组0.33%(RR 2.33,95%CI 1.28-4.27,P=.005)。
  • 调整混杂后毛果芸香碱使用与RRD风险增加相关(HR 3.14,95%CI 1.66-5.93,P<.001)。

核心结论

  • 本研究量化了局部毛果芸香碱使用与孔源性视网膜脱离风险增加之间的关联。

研究设计与样本

  • 回顾性临床队列研究,使用TriNetX电子健康记录网络,纳入40岁以上首次使用局部毛果芸香碱(1.25%或任何剂量且排除其他适应症)的成人患者,对照组为开始使用人工泪液且无局部毛果芸香碱使用史的老视患者,采用倾向性评分匹配基于人口学、系统合并症和已知RRD危险因素进行匹配。

主要发现

  • 匹配后3个月RRD风险毛果芸香碱组0.53% vs 对照组0.25%(RR 2.18,95%CI 1.07-4.45,P=.03)。
  • 6个月RRD风险毛果芸香碱组0.60% vs 对照组0.31%(RR 1.93,95%CI 1.01-3.67,P=.04)。
  • 1年RRD风险毛果芸香碱组0.78% vs 对照组0.33%(RR 2.33,95%CI 1.28-4.27,P=.005)。
  • Cox比例风险模型显示,调整人口学和合并症后,毛果芸香碱使用与RRD风险增加相关(HR 3.14,95%CI 1.66-5.93,P<.001)。
  • 其他RRD危险因素包括男性(aHR 2.36,P=.001)、近视(aHR 2.36,P=.001)、玻璃体变性(aHR 2.22,P=.020)、格子样变性(aHR 3.71,P=.010)和人工晶状体眼(aHR 3.48,P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the association between topical pilocarpine and the risk of new-onset rhegmatogenous retinal detachment (RRD). DESIGN: Retrospective clinical cohort study. METHODS: We used an aggregated electronic health records research network, TriNetX, to examine the risk of RRD (ICD-10: H33.0x) following the initiation of pilocarpine. The primary study group included adult patients over 40 years who received topical pilocarpine (1.25% or any dose with the exclusion of other indications) for the first time. Our control group consisted of patients with presbyopia who were started on artificial tears and had no history of topical pilocarpine use during the study period. We matched both cohorts using propensity score matching (PSM) based on demographics, systemic comorbidities, and known risk factors for RRD. RESULTS: After matching, the three-month risk of RRD was significantly higher in the pilocarpine group (0.53%) compared to the control (0.25%) (RR: 2.18, 95% CI: 1.07-4.45, P = .03). The 6-month risk of RRD remained elevated at 0.60% in the study group versus 0.31% in the control group (RR: 1.93, 95% CI: 1.01-3.67, P = .04). At one year, the risk increased to 0.78% in the pilocarpine group and 0.33% in the control group (RR: 2.33, 95% CI: 1.28-4.27, P = .005). A Cox proportional hazards model indicated that pilocarpine use was associated with a 3.14-fold increased risk of RRD (95% CI: 1.66-5.93, P < .001) compared to controls after adjusting for demographics and comorbidities. Additional risk factors for RRD included male sex (aHR: 2.36, P = .001), myopia (aHR: 2.36, P = .001), vitreous degeneration (aHR: 2.22, P = .020), lattice degeneration (aHR: 3.71, P = .010), and pseudophakia (aHR: 3.48, P < .001). CONCLUSIONS: Our study quantified the increased risk of RRD associated with topical pilocarpine use.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Elhusseiny AM, Chauhan MZ, Jabbehdari S, et al. Using Real-World Data to Assess the Association of Retinal Detachment With Topical Pilocarpine Use. Am J Ophthalmol. 2024. PMID: 39510368. doi:10.1016/j.ajo.2024.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。